Evaluate the short-term safety and feasibility of recombinant mutant human tumor necrosis factor (rmhTNF) for intraoperative intraperitoneal perfusion therapy in patients with advanced colon cancer.

Prospective inclusion of case data from 50 patients with advanced colon cancer who underwent surgical treatment at the Colorectal Surgery Department of the National Cancer Center/Cancer Hospital of the Chinese Academy of Medical Sciences between January 2022 and April 2023. The study group was divided into a study group and a control group based on whether rmhTNF was infused into the abdominal cavity, with 25 cases in each group. The study group received rmhTNF intraperitoneal infusion treatment through a drainage tube after abdominal closure, The control group was rinsed with distilled water in the abdominal cavity. Analyze the differences in clinical indicators between two groups of patients.

There was no significant differences in the incidence of postoperative complications, time of gastrointestinal function recovery, blood toxicity, liver and kidney function, coagulation function, and inflammatory markers between the two groups (all P>0.05).

The use of rmhTNF for intraoperative intraperitoneal perfusion therapy in advanced colon cancer patients has good safety and tolerability, does not affect postoperative gastrointestinal function recovery and increase the incidence of recent postoperative complications, has no effect on liver and kidney function, coagulation function, inflammatory indicators, and has no hematological toxicity.